Coherus BioSciences (CHRS) 8-K First Quarter 2019 Financial Results

Exhibit 99.1

Coherus BioSciences Reports Corporate Highlights and

First Quarter 2019 Financial Results

REDWOOD CITY, Calif., May 9, 2019 – Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today reviewed corporate highlights and reported financial results for the quarter ended March 31, 2019.

First Quarter 2019 Company Highlights

• UDENYCA^® (pegfilgrastim-cbqv) Launch Performance Consistent with Plan

• Net product revenue for the first quarter of 2019 was $37.1 million following Coherus’ successful launch of UDENYCA^® in the U.S. marketplace on January 3, 2019.

• Uptake of UDENYCA^® in 340B hospitals,non-340B hospitals and community oncology clinics is in line with the Company’s expectations.

• UDENYCA^® launch performance validates its broad value proposition approach and the commercial strategy Coherus implemented. This comprehensive branded biosimilar approach leverages Coherus’ robust commercial infrastructure and its comprehensive support services program, Coherus Completewww.coheruscomplete.com.

• The Company secured transitional pass-through status in 340B hospitals from CMS effective April 1, 2019, granted for a period of 36 months, incentivizing access to UDENYCA^® for Medicare patients.

• The Company secured a $75 million credit financing with Healthcare Royalty Partners to accelerate the manufacturing and launch of UDENYCA^®.

• Legal Developments

• Coherus and Amgen settled the trade secret action brought by Amgen and Coherus continues to commercialize UDENYCA^® across all segments.

• The Company announced a global settlement with AbbVie securing rights to commercialize its adalimumab biosimilar candidate,CHS-1420, affording a U.S. market entry date of December 15, 2023.

• The Company announced the filing of a patent infringement suit against Amgen directed to Amgen’s Humira^® biosimilar formulation.

First Quarter 2019 Financial Results

• Net product revenuefor the first quarter of 2019 was $37.1 million. Cost of goods soldfor the first quarter of 2019 was $2.2 million, resulting in a gross profit margin of 94 percent for the first quarter of 2019.

• Research and development (R&D)expenses for the first quarter of 2019 were $18.8 million, as compared to $25.5 million for the same period in 2018. The decreases in R&D expenses were mainly due to the capitalization of UDENYCA^® manufacturing in the first quarter of 2019.

• Selling, general and administrative (SG&A) expenses for the first quarter of 2019 were $32.7 million, as compared to $16.6 million for the same period in 2018. The increase in SG&A expenses in 2019, which was mainly attributable to the costs associated with commercializing UDENYCA^® in the U.S.

• Total operating expensesdecreased by $6.8 million from $60.5 million in the fourth quarter of 2019 to $53.7 million in the first quarter of 2019 primarily as a result of a reduction in UDENYCA^® manufacturingpre-approval activities.

• Cash and cash equivalents and investments in marketable securitiesfor the first quarter totaled $96.4 million as of March 31, 2019, as compared to $95.2 million as of March 31, 2018, and $72.4 million as of December 31, 2018.

• Net lossattributable to the Companyfor the first quarter of 2019 was ($20.0) million, or ($0.29) per share, compared to a net loss of ($44.3) million, or ($0.74) per share, for the same period in 2018.

Guidance for the Next Nine Months from March 31, 2019

• UDENYCA^® (pegfilgrastim-cbqv) biosimilar to Neulasta^® (pegfilgrastim)

• Increase the breadth and depth of adoption across all market segments.

• Secure reimbursement coverage among remaining national and regional payers.

• CHS-1420, biosimilar candidate to Humira^® (adalimumab)

• Pursue manufacturing objectives in support of the anticipated filing of a 351(k) biologic license application (BLA) in the U.S.

• CHS-3351, biosimilar candidate to Lucentis^® (ranibizumab) andCHS-2020, biosimilar candidate to Eylea^® (aflibercept)

• Complete manufacturing technology transfer to support clinical development ofCHS-3351.

• Continue preclinical development ofCHS-2020.

• CHS-131, small molecule,PPAR-gmodulator drug candidate in nonalcoholic steatohepatitis (“NASH”)

• Initiate clinical phase program in NASH.

Conference Call Information

When: Thursday, May 9, 2019 starting at 4:30 p.m. ET

Dial-in: (844)452-6826 (toll free) or (765)507-2587 (international)

Conference ID: 2969536

Webcast:http://investors.coherus.com

You will be asked to register when you join the call. The webcast will be archived on the Coherus website.

About UDENYCA^®

UDENYCA^® (pegfilgrastim-cbqv) is a PEGylated growth colony-stimulating factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients withnon-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. UDENYCA^®drug substance manufacturing is located in Boulder, Colorado. Pegfilgrastim is one of the largest selling oncology biologics with worldwide revenues in excess of $4.5 billion in 2017.

Indication

UDENYCA^® is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients withnon-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Limitations of Use

UDENYCA^® is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

IMPORTANT SAFETY INFORMATION

Contraindication

Patients with a history of serious allergic reaction to human granulocyte colony-stimulating factors such as pegfilgrastim or filgrastim products.

Warnings and Precautions

• Fatal splenic rupture: Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture.

• Acute respiratory distress syndrome (ARDS): Evaluate patients who develop fever, lung infiltrates, or respiratory distress. Discontinue UDENYCA^® in patients with ARDS.

• Serious allergic reactions, including anaphylaxis: Permanently discontinue UDENYCA^® in patients with serious allergic reactions.

• Fatal sickle cell crises: Have occurred.

• Glomerulonephritis: Evaluate and consider dose-reduction or interruption of UDENYCA^® if causality is likely.

Adverse Reactions

Most common adverse reactions (³ 5% difference in incidence compared to placebo) are bone pain and pain in extremity.

To report SUSPECTED ADVERSE REACTIONS, contact Coherus BioSciences, Inc. at1-800-4-UDENYCA(1-800-483-3692) or FDA at1-800-FDA-1088 orwww.fda.gov/medwatch.

Full Prescribing Information available at www.UDENYCA.com

About Coherus BioSciences, Inc.

Coherus BioSciences is a leading biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales and marketing and clinical-regulatory development, Coherus BioSciences is positioned as a leader in the global biosimilar marketplace. Coherus BioSciences commercializes UDENYCA^® (pegfilgrastim-cbqv) in the U.S. and has received regulatory approval for UDENYCA^® in the European Union. Coherus BioSciences is advancing two late-stage clinical products towards commercialization,CHS-1420 (adalimumab biosimilar) andCHS-0214 (etanercept biosimilar), and developing a robust pipeline of future products in ophthalmology (includingCHS-3351, a ranibizumab biosimilar, andCHS-2020, an aflibercept biosimilar), as well asCHS-131, a small molecule for nonalcoholic steatohepatitis (NASH) and multiple sclerosis. For additional information, please visitwww.coherus.com.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, transitional pass-through status in 340B hospitals from CMS incentivizing access to UDENYCA^®; being able to accelerate the manufacturing of UDENYCA^®; Coherus’ expectations regarding its ability to increase the breadth and depth of UDENYCA’s adoption across all market segments and to secure reimbursement coverage among remaining national and regional payers for UDENYCA^®; Coherus’ ability to pursue manufacturing objectives ofCHS-1420 in support of an anticipated BLA; Coherus’ plan to complete the manufacturing technology transfer to support the clinical development ofCHS-3351; Coherus’ expectation to continue the preclinical development ofCHS-2020; and Coherus’ plan to initiate a clinical phase program forCHS-131 in NASH. Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus’ actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties inherent in the clinical drug development process; the risks and uncertainties of the regulatory approval process, including the timing of Coherus’ regulatory filings; the risk that Coherus is unable to complete commercial transactions and other matters that could affect the availability or commercial potential of Coherus’ biosimilar drug candidates; and the risks and uncertainties of possible patent litigation. All forward-looking statements contained in this press release speak only as of the date on which they were made. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business in general, see Coherus’ Quarterly Report on Form10-Q for the three months ended March 31, 2019, filed with the Securities and Exchange Commission on May 9, 2019 and its future periodic reports to be filed with the Securities and Exchange Commission. Our results for the quarter ended March 31, 2019 are not necessarily indicative of our operating results for any future periods.

UDENYCA^® is a trademark of Coherus BioSciences, Inc.

Neulasta^® is a registered trademark of Amgen Inc.

Humira^® is a registered trademark of AbbVie Inc.

Lucentis^® is a registered trademark of Genentech, Inc.

Eylea^® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Coherus BioSciences, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)

	Three Months Ended March 31,
	2019			2018
	(unaudited)
Revenue:
Net product revenue	$	37,098		$	—
Operating expenses:
Cost of goods sold		2,225			—
Research and development		18,789			25,455
Selling, general and administrative		32,683			16,577
Total operating expenses		53,697			42,032
Loss from operations		(16,599	)		(42,032	)
Interest expense		(4,216	)		(2,408	)
Other income, net		811			138
Net loss		(20,004	)		(44,302	)
Net loss attributable tonon-controlling interest		—			5
Net loss attributable to Coherus	$	(20,004	)	$	(44,297	)
Net loss per share attributable to Coherus, basic and diluted	$	(0.29	)	$	(0.74	)
Weighted-average number of shares used in computing net loss per share attributable to Coherus, basic and diluted		69,140,697			60,122,050

Coherus BioSciences, Inc.

Condensed Consolidated Balance Sheets

(in thousands)

	March 31, 2019			December 31, 2018
	(unaudited)
Assets
Cash and cash equivalents	$	81,515		$	72,356
Investments in marketable securities - short-term		14,918			—
Trade receivables, net		46,476			—
Other assets		43,206			27,111
Total assets	$	186,115		$	99,467
Liabilities and Stockholders’ Deficit
Convertible notes	$	77,614		$	77,319
Convertible notes - related parties		25,872			25,773
Term loan		73,124			—
Other liabilities		48,020			34,966
Total stockholders’ deficit		(38,515	)		(38,591	)
Total liabilities and stockholders’ deficit	$	186,115		$	99,467

Contact

David S. Arrington

VP, Investor Relations & Corporate Affairs

Coherus BioSciences, Inc.

darrington@coherus.com

+1 (650)395-0196